Your browser doesn't support javascript.
loading
Minimal important difference of the 6-minute walk test after allogenic hematopoietic stem cell transplantation.
Murao, Masanobu; Kondo, Tadakazu; Hamada, Ryota; Miyasaka, Junsuke; Matsushita, Michiko; Otagaki, Ayumi; Kajimoto, Taishi; Arai, Yasuyuki; Kanda, Junya; Nankaku, Manabu; Ikeguchi, Ryosuke; Takaori-Kondo, Akifumi; Matsuda, Shuichi.
Afiliación
  • Murao M; Rehabilitation Unit, Kyoto University Hospital, Kyoto, Japan.
  • Kondo T; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Hamada R; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Miyasaka J; Rehabilitation Unit, Kyoto University Hospital, Kyoto, Japan.
  • Matsushita M; Rehabilitation Unit, Kyoto University Hospital, Kyoto, Japan.
  • Otagaki A; Rehabilitation Unit, Kyoto University Hospital, Kyoto, Japan.
  • Kajimoto T; Rehabilitation Unit, Kyoto University Hospital, Kyoto, Japan.
  • Arai Y; Rehabilitation Unit, Kyoto University Hospital, Kyoto, Japan.
  • Kanda J; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Nankaku M; Department of Clinical Laboratory Medicine, Faculty of Medicine, Kyoto University, Kyoto, Japan.
  • Ikeguchi R; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Takaori-Kondo A; Rehabilitation Unit, Kyoto University Hospital, Kyoto, Japan.
  • Matsuda S; Rehabilitation Unit, Kyoto University Hospital, Kyoto, Japan.
Disabil Rehabil ; : 1-8, 2023 Aug 13.
Article en En | MEDLINE | ID: mdl-37574839
Advancements in allogeneic hematopoietic stem cell transplantation have improved the survival rates of individuals with malignant hematological disorders, and efforts should now be focused on enhancing their physical function and quality of life.There is a problem that the physical performance of the patients is reduced by the side effects of treatment.More careful follow-up after discharge is necessary for allo-HSCT patients who show a reduction of 37.5 m or more in the acute illness phase.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Disabil Rehabil Asunto de la revista: REABILITACAO Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Disabil Rehabil Asunto de la revista: REABILITACAO Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido